25 results on '"Lafeber, Melvin"'
Search Results
2. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
- Author
-
Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, Koopmans, Marion P. G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.
- Published
- 2024
- Full Text
- View/download PDF
3. Association between Clinical Frailty Scale and mortality 24 months after hospitalisation in adult patients with COVID-19
- Author
-
Aleman, Jacomien, Tournoy, Jos, Van der Linden, Lorenz, Gambera, Marco, Martignoni, Isabella, Van Etten, Ronald, van Onzenoort, Hein, Kappers, Mariette, van Wijngaarden, Peter, Verstijnen, Jose, Theeuwes, Vera, Kemper, Marleen, Slob, Elise, Sombogaard, Ferdi, Abdullah-Koolmees, Heshu, van den Berg, Roland, de Wit, Hugo, Dilek, Betul, Hogenhuis, Freija, Buyukayten, Vahid, te Brake, Britt, Nieuwenhuijzen, Margriet, Scheeren, Maria, de Wit, Madelief, Bulsink, Arjan, van Haelst, Ingrid, ter Horst, Peter, Moorlag, Rosalie, Vos, Anja, Otten-Helmers, Annemiek, van Kan, Erik, Voskamp, Marije, Ebbens, Marieke, Ezinga, Marieke, van Nieuwkoop, Cees, Visser, Loes, Ghazarian, Caroline, Hilarius, Doranne, Hermanides, Gonneke, Bresser, Carlinda, Derijks-Engwegen, Judith, Boemaars, Ebbie, Getrouw, Zahira, Maat, Barbara, Wierenga, Peter, Bosch, Tessa, Krens, Lisanne, Liang, Kajie, Saleh, Langeza, van Heuckelum, Milou, Hendriksen, Linda, van der Linden, Paul, Guda, Kaylen, Crommentuijn, Kristel, Cornelissen-Wesseling, Ilse, Diepstraten, Jeroen, Ellerbroek, Jacobien, Coenradie, Saskia, Deben, Debbie, Hurkens, Kim, Wong, Dennis, Vromen, Marion, de Bock, Marjolein, Savelkoul, Suzan, Wolters, Saskia, Andrews, Louise, Jong, Eefje, Kranenburg, Rosanne, Soares, Joana, Falcao, Fatima, Solano, Mariana, Viegas, Erica, Falcao, Margarida, Farinha, Helena, Mendes, Dina, Rijo, Joao, Miarons, Marta, Gorgas, Maria Queralt, Yubero, Cristina García, Portillo Horcajada, Laura, Keijzers, Kim, Lim, Silke, Ashfield, Linden, Bell, Helen, Fitzhugh, Naomi, Fleming, Glenda, Goodfellow, Nicola, Hanley, Joanne, Scott, Michael, Mooijaart, Simon P., Gussekloo, Jacobijn, Elders, Petra, Peeters, Geeske, Minnema, Julia, Lafeber, Melvin, Sablerolles, Roos S.G., van Kempen, Janneke A.L., Tap, Lisanne, Polinder-Bos, Harmke A., van de Loo, Bob P.A., van der Kuy, Hugo, and Faes, Miriam C.
- Published
- 2024
- Full Text
- View/download PDF
4. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
- Author
-
Azizi, Michel, Sharp, Andrew S.P., Fisher, Naomi D.L., Weber, Michael A., Lobo, Melvin D., Daemen, Joost, Lurz, Philipp, Mahfoud, Felix, Schmieder, Roland E., Basile, Jan, Bloch, Michael J., Saxena, Manish, Wang, Yale, Sanghvi, Kintur, Jenkins, J. Stephen, Devireddy, Chandan, Rader, Florian, Gosse, Philippe, Claude, Lisa, Augustin, Dimitri A., McClure, Candace K., Kirtane, Ajay J., Wang, Yale, Skeik, Nedaa, Bae, Richard, McMeans, Amy, Goldman, JoAnne, Peterson, Rose, Stephen Jenkins, James, Tutor, Isabelle, Harrison, Michael, Penning, Angel, Devireddy, Chandan, Lea, Janice, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Tran, Anne, Bhatia, Kirin, Fisher, Naomi D.L., Sobieszczyk, Piotr, Halliday, Ian, Munson, Tay, Lindsey, Jason, Laster, Steven, Bunte, Mathew, Hart, Anthony, King, Dana, Hall, Jamie, Sanghvi, Kintur, Krathen, Courtney, Lewis, Luot, Willitts, Ashley, Todoran, Thomas, Basile, Jan, Awkar, Anthony, Palmer, Casey, Tecklenburg, Anna, Schindler, John, Pacella, John, Muldoon, Matthew, Albright, MaryJo, Nicholson, Tracy, Flack, John, Chami, Youseff, Hafiz, Abdul Moiz, Starkey, Emily, Adams, Kristal, Bernardo, Nelson, Veis, Judith, Hashim, Hayder, Singh, Suman, Whitman, Donna, Stouffer, Rick, Hinderliter, Alan, Allen, Meghan, Scholl, Tatum, Fong, Pete, Gainer, James, Crook, Sherron, Hatchcock, Ellen, Cohen, Debbie, Giri, Jay, Kobayashi, Taisei, Neubauer, Robin, Naidu, Suveeksha, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Khuddus, Matheen, Zentko, Suzanne, Touchton, Abby, Roberson, Marti, Bloch, Michael J., Akinapelli, Abhilash, English, Lisa, Neumann, Bridget, Mendelsohn, Farrel, Brantley, Hutton, Cawthon, Thomas, DeRamus, Susan, Wade, Wesley, Fishman, Robert, Tuohy, Edward, LeBlanc, Jessica, McCurry, Tina, Krishnaswamy, Amar, Laffin, Luke, Bajzer, Christopher, Boros, Marilyn, Branche, Monica, Abraham, Josephine, Abraham, Anu, Stijleman, Inge, Hsi, David, Martin, Scott, Portnay, Edward, Fiebach, Maryann, Garavito, Carolina, Adams, Todd, Teklinski, Andrew, Leech, Adam, Drilling, Patrick, Tulik, Lynda, Benzuly, Keith, Paparello, James, Fintel, Dan, Ramirez, Haydee, Kats, Lauren, Huang, Paul, Biswas, Santanu, Risher, Serena, Pratt, Kristina, Ibebuogu, Uzoma, Johnson, Karen, Cushman, William, Jones, Lisa, Jackson, Leigh, Landers, David, Pasala, Tilak, Salazer, Thomas, Canino, Peter, Arakelian, Patricia, Yang, Yi-Ming, Khaliq, Asma, Weinberg, Mitchell, Abetu, Yihenew, Gulliver, Alana, Reilly, J.P., Garasic, Joseph, Chugh, Atul, Bertolet, Barry, Go, Brian, Gallapudi, Raghava, Cohn, Joel, Rogers, Kevin, Saxena, Manish, Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Oliver, Topham, Christine, Sharp, Andrew, Anderson, Richard, Thompson, Elizabeth, Spiro, Nikki, Hodges, Elizabeth, Holder, Jaqueline, Ellam, Timothy, Bagnall, Alan, Jackson, Ralph, Bridgett, Victoria, Wilson, Peter, Das, Neelanjan, Doulton, Timothy, Loader, David, Hector, Gemma, Levy, Terry, Bent, Clare, Kodoth, Vivek, Horler, Stephanie, Nix, Sara, Robinson, Nicholas, Al-Janabi, Firas, Sayer, Jeremy, Ganesh Iyer, Sudha, Redman, Emily, Ramirez, Jonaifah, Padmanabhan, Sandosh, Sharif, Faisal, Alhmoudi, Aishah, Lunardi, Mattia, Coen, Eileen, Glynn, Nicola, Mahfoud, Felix, Lauder, Lucas, Kulenthiran, Saarraaken, Koch, Christina, Wachter, Angelika, Schmieder, Roland, Schmid, Axel, Kannenkeril, Dennis, Heinritz, Ulrike, Endres-Frohlich, Kerstin, Lurz, Philipp, Rommel, Karl, Fengler, Petzold, Martin, Büttner, Margit, Weil, Joachim, Agdirlioglu, Tolga, Köllner, Tanja, Stephan, Jeannine, Dagkonakis, Nikolaos, Hamann, Frank, Ettl, Ute, Petzsche, Ulrike, Reimer, Peter, Hausberg, Martin, Hinrichs, Ralf, Di Ponio-Voit, Isabella, Lutz, Matthias, Gosse, Philippe, Cremer, Antoine, Papadopoulos, Panteleimon, Gaudissard, Julie, Maire, Florent, Azizi, Michel, Sapoval, Marc, Livrozet, Marine, Regrag, Asma, Paquet, Valerie, Delsart, Pascal, Hennicaux, Justin, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Lafeber, Melvin, Zeijen, Victor, Ruiter, Amo, Huijskens, Elisabeth, van Ramshorst, Jan, Xaplanteris, Panagiotis, Briki, Rachid, de Hemptinne, Quentin, Pascal, Severine, Renard, Katty, Ferdinande, Bert, Iglesias, Juan F., Ehert, Georg, Gallego, Laetitia, Dobretz, Kevin, Bottone, Sylviane, Sanghvi, Kintur, Costello, Josh, Krathan, Courtney, Lewis, Luot, McElvarr, Andrew, Reilly, John, Jenkins, Stephen, Cash, Michael, Williams, Shannon, Jarvis, Maria, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Crook, Sherron, Maddel, Sarita, Hsi, David, Martin, Scott, Portnay, Edward, Ducey, Maryanne, Rose, Suzanne, DelMastro, Elizabeth, Bangalore, Sripal, Williams, Stephen, Cabos, Stanley, Rodriguez Alvarez, Carolina, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Paladugu, Vijay, Tecklenburg, Anna, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Kim, Hyun-Min, Rashid, Mohammad, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Lavasani, Iran, Neilson, Hailey, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Kinder, Sheila, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Do, Danny, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Foster, Abby, Boyette, Alice, Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Peterson, Rose, Goldman, Jo Anne, Goldman, Jessie, Ledley, Gary, Katof, Nancy, Potluri, Srinivasa, Biedermann, Scott, Ward, Jacquelyn, White, Megan, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Smith, Alex, Aseltine, Laura, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Wade, Tyrone, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Semenec, Terence, Bloch, Michael J., Roongsritong, Chanwit, Nelson, Priscilla, Neumann, Bridget, Cohen, Debbie, Giri, Jay, Neubauer, Robin, Vo, Thu, Chugh, Atul R., Huang, Pei-Hsiu, Jose, Powell, Flack, John, Fishman, Robert, Jones, Michael, Adams, Todd, Bajzer, Christopher, Saxena, Manish, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Olivier, Levy, Terry, Bent, Clare, Beckett, David, Lakeman, Nicki, Kennard, Sarah, Sharp, Andrew, D’Souza, Richard J., Statton, Sarah, Wilkes, Lindsay, Anning, Christine, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Sevillano, Annaliza, Ocampo, Madelaine, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Sinclair, Janet, Pepper, Hayley, Davies, Justin, Chapman, Neil, Burak, Paula, Carvelli, Paula, Jadhav, Sachin, Quinn, Jane, Christian Rump, Lars, Stegbauer, Johannes, Schimmöller, Lars, Potthoff, Sebastian, Schmid, Claudia, Roeder, Sylvia, Weil, Joachim, Hafer, Lukas, Agdirlioglu, Tolga, Köllner, Tanja, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Kulenthiran, Saarraaken, Wachter, Angelika, Koch, Christina, Lurz, Philipp, Fengler, Karl, Rommel, Karl-Philipp, Trautmann, Kai, Petzold, Martin, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Heinritz, Ulrike, Fröhlich-Endres, Kerstin, Genth-Zotz, Sabine, Kämpfner, Denise, Grawe, Armin, Höhne, Johannes, Kaesberger, Bärbel, von zur Mühlen, Constantin, Wolf, Dennis, Welzel, Markus, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Maire, Florent, Gaudissard, Julie, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Livrozet, Marine, Lorthioir, Aurélien, Paquet, Valérie, Pathak, Atul, Honton, Benjamin, Cottin, Marianne, Petit, Frédéric, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Langevin, Fatou, Delsart, Pascal, Longere, Benjamin, Ledieu, Guillaume, Pontana, François, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Feyz, Lida, Zeijen, Victor, Ruiter, Arno, Huyskens, Elisabeth, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Dolmans, Helma, Kroon, A.A., van Zwam, W.H., Vranken, Jeannique, de Haan, Claudia, Persu, Alexandre, Renkin, Jean, Maes, Frédéric, Beauloye, Christophe, Lengelé, Jean-Philippe, Huyberechts, Dominique, Bouvier, Anne, Witkowski, Adam, Januszewicz, Andrzej, Kądziela, Jacek, Prejbisj, Aleksander, Hering, Dagmara, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Owczuk, Radoslaw, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Rader, Florian, Dohad, Suhail, Victor, Ronald, Sanghvi, Kintur, Costello, Josh, Walsh, Courtney, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Williams, Jonathan, Bloch, Michael J., Roongsritong, Chanwit, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Reilly, John, Cash, Michael, Goldman, Jessie, Aggarwal, Sandeep, Ledley, Gary, Hsi, David, Martin, Scott, Portnay, Edward, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Huang, Pei-Hsiu, Jose, Powell, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Potluri, Srinivasa, Biedermann, Scott, Bangalore, Sripal, Williams, Stephen, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Kirtane, Ajay J., Radhakrishnan, Jai, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Ali Edroos, Sadat, Levy, Terry, Patel, Amit, Beckett, David, Bent, Clare, Davies, Justin, Chapman, Neil, Shun Shin, Matthew, Howard, James, Sharp, Andrew S.P., Joseph, Anil, D’Souza, Richard, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Elorz, Cristina, Lurz, Philipp, Höllriegel, Robert, Fengler, Karl, Rommel, Karl-Philipp, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Lucic, Jelena, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Rump, Christian, Stegbauer, Johannes, Kröpil, Patric, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Pathak, Atul, Honton, Benjamin, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Daemen, Joost, Feyz, Lida, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Kroon, A.A., van Zwam, W.H., Persu, Alexandre, and Renkin, Jean
- Published
- 2024
- Full Text
- View/download PDF
5. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
- Author
-
Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, and van der Kuy, P Hugo M
- Published
- 2023
- Full Text
- View/download PDF
6. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
- Author
-
Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.
- Published
- 2023
- Full Text
- View/download PDF
7. Adequacy of blood pressure control in high-risk hypertensive patients: The DEGREE study
- Author
-
Zeijen, Victor J.M., Lafeber, Melvin, Versmissen, Jorie, Kroon, Abraham A., Boersma, Eric, and Daemen, Joost
- Published
- 2022
- Full Text
- View/download PDF
8. Association between renal sympathetic denervation and arterial stiffness: the ASORAS study
- Author
-
Zeijen, Victor J.M., Feyz, Lida, Kardys, Isabella, Geleijnse, Marcel L., Van Mieghem, Nicolas M., Zijlstra, Felix, Lafeber, Melvin, Van Der Geest, Rob J., Hirsch, Alexander, and Daemen, Joost
- Published
- 2023
- Full Text
- View/download PDF
9. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
- Author
-
Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, de Vries, Rory D, Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, and de Vries, Rory D
- Abstract
Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies.
- Published
- 2024
10. Monitoring antihypertensive drug concentrations to determine nonadherence in hypertensive patients with or without a kidney transplant
- Author
-
Peeters, Laura E.J., primary, Hesselink, Dennis A., additional, Lafeber, Melvin, additional, Severs, David, additional, van den Hoogen, Martijn W.F., additional, Sonneveld, Michelle A.H., additional, Ramakers, Christian R.B., additional, Bahmany, Soma, additional, van Gelder, Teun, additional, Koch, Birgit C.P., additional, and Versmissen, Jorie, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON):results from the direct boost group of an open-label, multicentre, randomised controlled trial
- Author
-
Tan, Ngoc H., Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, Geurts van Kessel, Corine H., de Vries, Rory D, van der Kuy, P Hugo M, Tan, Ngoc H., Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, Geurts van Kessel, Corine H., de Vries, Rory D, and van der Kuy, P Hugo M
- Abstract
Background: Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron spike (S) protein were developed as a countermeasure against antigenically distinct SARS-CoV-2 variants. We aimed to assess the (variant-specific) immunogenicity and reactogenicity of mRNA-based bivalent omicron (BA.1) vaccines in individuals who were primed with adenovirus-based or mRNA-based vaccines encoding the ancestral spike protein. Methods: We analysed results of the direct boost group of the SWITCH ON study, an open-label, multicentre, randomised controlled trial. Health-care workers from four academic hospitals in the Netherlands aged 18–65 years who had completed a primary COVID-19 vaccination regimen and received one booster of an mRNA-based vaccine, given no later than 3 months previously, were eligible. Participants were randomly assigned (1:1) using computer software in block sizes of 16 and 24 to receive an omicron BA.1 bivalent booster straight away (direct boost group) or a bivalent omicron BA.5 booster, postponed for 90 days (postponed boost group), stratified by priming regimen. The BNT162b2 OMI BA.1 boost was given to participants younger than 45 years, and the mRNA-1273.214 boost was given to participants 45 years or older, as per Dutch guidelines. The direct boost group, whose results are presented here, were divided into four subgroups for analysis: (1) Ad26.COV2.S (Johnson & Johnson) prime and BNT162b2 OMI BA.1 (BioNTech–Pfizer) boost (Ad/P), (2) mRNA-based prime and BNT162b2 OMI BA.1 boost (mRNA/P), (3) Ad26.COV2.S prime and mRNA-1273.214 (Moderna) boost (Ad/M), and (4) mRNA-based prime and mRNA-1273.214 boost (mRNA/M). The primary outcome was fold change in S protein S1 subunit-specific IgG antibodies before and 28 days after booster vaccination. The primary outcome and safety were assessed in all participants except those who withdrew, had a SARS-CoV-2 breakthrough infection, or had a missing blood sample at day 0 or day 28. This tria
- Published
- 2023
12. Association between renal sympathetic denervation and arterial stiffness:the ASORAS study
- Author
-
Zeijen, Victor J M, Feyz, Lida, Kardys, Isabella, Geleijnse, Marcel L, Van Mieghem, Nicolas M, Zijlstra, Felix, Lafeber, Melvin, Van Der Geest, Rob J, Hirsch, Alexander, Daemen, Joost, Zeijen, Victor J M, Feyz, Lida, Kardys, Isabella, Geleijnse, Marcel L, Van Mieghem, Nicolas M, Zijlstra, Felix, Lafeber, Melvin, Van Der Geest, Rob J, Hirsch, Alexander, and Daemen, Joost
- Abstract
OBJECTIVES: Renal sympathetic denervation (RDN) reduces blood pressure (BP). However, one out of three patients does not exhibit a significant BP response to the therapy. This study investigates the association between noninvasive vascular stiffness indices and RDN-mediated BP reduction.METHODS: In this prospective, single-arm pilot study, patients with systolic office BP at least 140 mmHg, mean 24-h systolic ambulatory blood pressure (ABP) at least 130 mmHg and at least three prescribed antihypertensive drugs underwent radiofrequency RDN. The primary efficacy endpoint was temporal evolution of mean 24-h systolic ABP throughout 1-year post RDN (measured at baseline and 3-6-12 months). Effect modification was studied for baseline ultrasound carotid-femoral and magnetic resonance (MR) pulse wave velocity (PWV), MR aortic distensibility, cardiac MR left ventricular parameters and clinical variables. Statistical analyses were performed using linear mixed-effects models, and effect modification was assessed using interaction terms.RESULTS: Thirty patients (mean age 62.5 ± 10.7 years, 50% women) with mean 24-h ABP 146.7/80.8 ± 13.7/12.0 mmHg were enrolled. Following RDN, mean 24-h systolic ABP changed with -8.4 (95% CI: -14.5 to -2.3) mmHg/year (P = 0.007). Independent effect modifiers were CF-PWV [+2.7 (0.3 to 5.1) mmHg/year change in outcome for every m/s increase in CF-PWV; P = 0.03], daytime diastolic ABP [-0.4 (-0.8 to 0.0) mmHg/year per mmHg; P = 0.03], age [+0.6 (0.2 to 1.0) mmHg/year per year of age; P = 0.006], female sex [-14.0 (-23.1 to -5.0) mmHg/year as compared with men; P = 0.003] and BMI [+1.2 (0.1 to 2.2) mmHg/year per kg/m2; P = 0.04].CONCLUSION: Higher CF-PWV at baseline was associated with a smaller reduction in systolic ABP following RDN. These findings could contribute to improve identification of RDN responders.
- Published
- 2023
13. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
- Author
-
Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., and GeurtsvanKessel, Corine H.
- Abstract
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.
- Published
- 2023
14. Wanneer gaan we patiënten een ‘polypil’ geven?
- Author
-
Lafeber, Melvin, Peeters, Laura, Versmissen, Jori, Pharmacy, and Internal Medicine
- Abstract
The 'polypill' stands for fixed-dosed combination pills with generic drugs that act on multiple cardiovascular risk factors. Data from randomized controlled trials show consistent beneficial effects of treatment with a polypill on both cardiovascular risk factors and relevant marjor cardiovascular endpoints. However, polypills are not readily available worldwide and only a limited number of polypills is marketed in Europe. Physicians have to embrace polypills in regular care to let the patient benefit from the advantages of the polypill. Licensing more polypills is an essential step to implement these pills in clinical care. Regulatory agencies need to reduce the dossier content requirements for registrations of new fixed-dosed combination pills so generic pharmaceutical companies can expand the number of marketed polypills.
- Published
- 2023
15. Nocebo-effecten van statines
- Author
-
Lafeber, Melvin, Evers, Andrea W M, Klok, Frederikus A, Pharmacy, Internal Medicine, and Health Economics (HE)
- Abstract
Statins are effective drugs that can reduce the risk of new cardiovascular events. Although in randomized, placebo-controlled trials statins are associated with a low risk of mild muscle complaints such as myalgia, in daily practice up to 30% of patients report complaints attributed to statin use. Two recent studies have shown statin-associated muscle complaints are mainly related to the nocebo effect. The nocebo effect is a decrease in benefit and/or a new onset or worsening of adverse effects due to an expectation of harm associated with the treatment. Statins face reputational challenges due to a vast amount of negative attention on the internet. We need to address the nocebo effect by managing the perception of statins and provide patients with objective information about statin treatment, reduce the negative expectations, and placing discussion about the likelihood of adverse effects into the context of treatment benefit.
- Published
- 2023
16. Measuring Antihypertensive Drug Concentrations to Determine Nonadherence in Hypertensive Patients with and Without Kidney Transplantation
- Author
-
Peeters, Laura E. J., Hesselink, Dennis A., de Winter, Brenda C. M., Lafeber, Melvin, Severs, David, van den Hoogen, Martijn W. F., Sonneveld, Michelle A. H., Ramakers, Chris R. B., Bahmany, Soma, van Gelder, Teun, Koch, Birgit C. P., Versmissen, Jorie, Pharmacy, Internal Medicine, and Clinical Chemistry
- Published
- 2023
17. PS-C27-3: MEASURING ANTIHYPERTENSIVE DRUG CONCENTRATIONS TO DETERMINE NON-ADHERENCE IN HYPERTENSIVE PATIENTS WITH AND WITHOUT KIDNEY TRANSPLANTATION
- Author
-
Peeters, Laura EJ, primary, Hesselink, Dennis A, additional, de Winter, Brenda CM, additional, Lafeber, Melvin, additional, Severs, David, additional, van den Hoogen, Martijn WF, additional, Sonneveld, Michelle AH, additional, Ramakers, Chris RB, additional, Bahmany, Soma, additional, van Gelder, Teun, additional, Koch, Birgit CP, additional, and Versmissen, Jorie, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
- Author
-
Tan, Ngoc H., primary, Sablerolles, Roos S. G., additional, Rietdijk, Wim J. R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Bogers, Susanne, additional, Geers, Daryl, additional, Zaeck, Luca M., additional, Koopmans, Marion P. G., additional, Dalm, Virgil A. S. H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L. W., additional, van Baarle, Debbie, additional, Lafeber, Melvin, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, Paul-Hugo Marie, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers:The SWITCH ON trial protocol
- Author
-
Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, van der Kuy, Hugo, Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, and van der Kuy, Hugo
- Abstract
Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05471440.
- Published
- 2022
20. Adequacy of blood pressure control in high-risk hypertensive patients:The DEGREE study
- Author
-
Zeijen, Victor J M, Lafeber, Melvin, Versmissen, Jorie, Kroon, Abraham A, Boersma, Eric, Daemen, Joost, Zeijen, Victor J M, Lafeber, Melvin, Versmissen, Jorie, Kroon, Abraham A, Boersma, Eric, and Daemen, Joost
- Abstract
INTRODUCTION: Hypertension is a modifiable risk factor in patients at the highest risk for cardiovascular events. New invasive treatment options are becoming available that might be particularly appealing for high-risk patients. Therefore, the aim of this study was to determine the prevalence of high-risk patients on routine therapy that do not meet guideline recommended ambulatory blood pressure (ABP) targets.METHODS: This single-center, cross-sectional study was conducted at the Erasmus University Medical Center (Rotterdam, The Netherlands). Inclusion criteria were: (1) age 18-80 years, (2) drugs prescribed for hypertension or history of hypertension and (3) high cardiovascular risk as defined according to the European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines. Patients underwent standardized office blood pressure (OBP) and same-day 24-h ABP measurements. Blood pressure (BP) control was defined according to the 2018 ESC/ESH and 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines.RESULTS: A total of 100 patients were enrolled (median age 71 years, 35% female). Mean OBP was 142.2/81.9 ± 18.6/12.6 mmHg and mean 24-h ABP was 126.1/70.1 ± 14.3/9.2 mmHg. Patients were on 2.0 [25th-75th percentile: 1.0-3.3] Defined Daily Doses of antihypertensive drugs. ESC/ESH guideline 24-h ABP and OBP targets were not met in 41.8% (95%CI: 31.5-52.6%) and 52.7% (95%CI: 42.0-63.3%), respectively. ACC/AHA guideline 24-h ABP and OBP targets were not met in 59.3% (95%CI: 48.5-69.5%) and 79.1% (95%CI: 69.3-86.9%), respectively.CONCLUSIONS: BP remains uncontrolled in 40-60% of high-risk hypertensive patients despite routine use of guideline-recommended therapy. Our findings support the search towards novel invasive BP lowering treatment options.
- Published
- 2022
21. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
- Author
-
Sablerolles, Roos S.G., primary, Rietdijk, Wim J.R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Geers, Daryl, additional, Schmitz, Katharina S., additional, Garcia Garrido, Hannah M., additional, Koopmans, Marion P.G., additional, Dalm, Virgil A.S.H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L.W., additional, Lafeber, Melvin, additional, van Baarle, Debbie, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, P. Hugo M., additional
- Published
- 2022
- Full Text
- View/download PDF
22. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
- Author
-
Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Schmitz, Katharina S, Geers, Daryl, Bogers, Susanne, Haren, Eva van, Koopmans, Marion P G, Dalm, Virgil A S H, Kootstra, Neeltje A, Huckriede, Anke L W, Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, Baarle, Debbie van, Vries, Rory D de, Kuy, P Hugo M van der, and GeurtsvanKessel, Corine H
- Subjects
COVID-19 ,IMMUNOGLOBULINS ,COVID-19 vaccines ,TIME ,IMMUNE system ,RESEARCH funding ,DRUG allergy - Abstract
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2–specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Association between Clinical Frailty Scale and mortality 24 months after hospitalisation in adult patients with COVID-19.
- Author
-
Minnema J, Lafeber M, Sablerolles RSG, van Kempen JAL, Tap L, Polinder-Bos HA, van de Loo BPA, van der Kuy H, and Faes MC
- Abstract
Background: The clinical frailty scale (CFS) was used as a triage tool for medical decision making during the COVID-19 pandemic. The CFS has been posed as a suitable risk marker for in-hospital mortality in COVID-19 patients. We evaluated whether the CFS is associated with mortality 24 months after hospitalisation for COVID-19., Methods: The COvid MEdicaTion (COMET) study is an international, multicentre, observational cohort study, including adult patients hospitalised for COVID-19 between March 2020-July 2020. Patients' characteristics, prescribed medication, clinical characteristics, and CFS were collected at admission, survival data were collected 24 months after hospitalisation. Multivariable cox proportional hazard models stratified by age (<65 and ≥65 years), and adjusted for covariates (age, sex, number of drugs, and types of drug class as a proxy for comorbidities) were used to study the association between the CFS and 24-month mortality after hospitalisation., Results: In this study, 1238 fit (CFS 1-3), 478 mildly frail (CFS 4-5), and 235 frail (CFS 6-9) patients were included for baseline analysis (median age 68 years (IQR 58-78); 58.5 % male). Frailty was associated with an increased risk of 24-month mortality after hospitalisation in older patients (HR 1.91, 95 % CI [1.17-3.12]), in younger adults a trend was seen (HR 3.13, 95 % CI [0.86-11.36])., Conclusion: The results suggest that the CFS is an indicator for mortality 24 months after hospitalisation in COVID-19 patients., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Hugo van der Kuy reports financial support was provided by 10.13039/501100001826Netherlands Organisation for Health Research and Development. Hugo van der Kuy reports financial support was provided by LOEY Foundation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
24. [When will we treat patients with a polypill shortly after myocardial infarction?]
- Author
-
Lafeber M, Peeters L, and Versmissen J
- Subjects
- Humans, Drug Combinations, Europe, Antihypertensive Agents therapeutic use, Cardiovascular Diseases etiology, Myocardial Infarction complications
- Abstract
The 'polypill' stands for fixed-dosed combination pills with generic drugs that act on multiple cardiovascular risk factors. Data from randomized controlled trials show consistent beneficial effects of treatment with a polypill on both cardiovascular risk factors and relevant marjor cardiovascular endpoints. However, polypills are not readily available worldwide and only a limited number of polypills is marketed in Europe. Physicians have to embrace polypills in regular care to let the patient benefit from the advantages of the polypill. Licensing more polypills is an essential step to implement these pills in clinical care. Regulatory agencies need to reduce the dossier content requirements for registrations of new fixed-dosed combination pills so generic pharmaceutical companies can expand the number of marketed polypills.
- Published
- 2023
25. [How to cope with the nocebo effects of statins?]
- Author
-
Lafeber M, Evers AWM, and Klok FA
- Subjects
- Humans, Nocebo Effect, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Drug-Related Side Effects and Adverse Reactions
- Abstract
Statins are effective drugs that can reduce the risk of new cardiovascular events. Although in randomized, placebo-controlled trials statins are associated with a low risk of mild muscle complaints such as myalgia, in daily practice up to 30% of patients report complaints attributed to statin use. Two recent studies have shown statin-associated muscle complaints are mainly related to the nocebo effect. The nocebo effect is a decrease in benefit and/or a new onset or worsening of adverse effects due to an expectation of harm associated with the treatment. Statins face reputational challenges due to a vast amount of negative attention on the internet. We need to address the nocebo effect by managing the perception of statins and provide patients with objective information about statin treatment, reduce the negative expectations, and placing discussion about the likelihood of adverse effects into the context of treatment benefit.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.